JP2005528374A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528374A5
JP2005528374A5 JP2003581743A JP2003581743A JP2005528374A5 JP 2005528374 A5 JP2005528374 A5 JP 2005528374A5 JP 2003581743 A JP2003581743 A JP 2003581743A JP 2003581743 A JP2003581743 A JP 2003581743A JP 2005528374 A5 JP2005528374 A5 JP 2005528374A5
Authority
JP
Japan
Prior art keywords
alkyl
carbon atoms
group
amino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003581743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003434 external-priority patent/WO2003084503A2/en
Publication of JP2005528374A publication Critical patent/JP2005528374A/ja
Publication of JP2005528374A5 publication Critical patent/JP2005528374A5/ja
Pending legal-status Critical Current

Links

JP2003581743A 2002-04-05 2003-04-02 粘液分泌過多の治療方法 Pending JP2005528374A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007699 2002-04-05
PCT/EP2003/003434 WO2003084503A2 (en) 2002-04-05 2003-04-02 P38 kinase inhibitors for treating mucus hypersecretion_

Publications (2)

Publication Number Publication Date
JP2005528374A JP2005528374A (ja) 2005-09-22
JP2005528374A5 true JP2005528374A5 (ru) 2006-06-01

Family

ID=28685842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003581743A Pending JP2005528374A (ja) 2002-04-05 2003-04-02 粘液分泌過多の治療方法

Country Status (14)

Country Link
EP (1) EP1494645A2 (ru)
JP (1) JP2005528374A (ru)
KR (1) KR20040101398A (ru)
CN (1) CN1658834A (ru)
AU (1) AU2003224025A1 (ru)
BR (1) BR0309009A (ru)
CA (1) CA2479520A1 (ru)
IL (1) IL163737A0 (ru)
MX (1) MXPA04009605A (ru)
NZ (1) NZ536278A (ru)
PL (1) PL372963A1 (ru)
RU (1) RU2004132847A (ru)
WO (1) WO2003084503A2 (ru)
ZA (1) ZA200406910B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101529A1 (ja) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006137421A1 (ja) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 局所投与剤
FR2903774B1 (fr) * 2006-07-17 2008-09-05 Renault Sas Procede de validation d'un diagnostic de fontionnement d'un dispositif.
NZ591427A (en) 2008-10-02 2012-12-21 Respivert Ltd P38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010067131A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000055139A2 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
ATE376547T1 (de) * 1999-05-21 2007-11-15 Scios Inc Derivate des indol-typs als p38 kinase inhibitoren
NZ517578A (en) * 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
KR20020032591A (ko) * 1999-09-17 2002-05-03 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 라이노바이러스 감염에서의 csaid의 용도
JP4105948B2 (ja) * 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2002032862A2 (en) * 2000-10-19 2002-04-25 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of smoke inhalation
CA2490819A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US20040009990A1 (en) * 2001-11-09 2004-01-15 Higgins Linda S. Method to treat cystic fibrosis

Similar Documents

Publication Publication Date Title
RU2004133034A (ru) Новые фармацевтические композиции на основе антихолинергических средств и ингибиторов киназы р38
JP2005529098A5 (ru)
JP2002539198A5 (ru)
RU2001122111A (ru) Ароматические гетероциклические соединения в качестве противовоспалительных агентов
JP2004536845A5 (ru)
JP2003514808A5 (ru)
JP2005528374A5 (ru)
CA2352524A1 (en) Aromatic heterocyclic compounds as antiinflammatory agents
JP2005518447A5 (ru)
US20070099832A1 (en) Combination Therapy with p38 MAP Kinase Inhibitors and their Pharmaceutical Compositions
CA2511970A1 (en) Urea derivatives useful in the treatment of heart failure
TW200932249A (en) Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
JP2008525502A5 (ru)
JP2005503400A5 (ru)
JP2008509177A5 (ru)
HUP0301576A2 (hu) A Neutrofilek IL-8 által indukált kemotaxisának gátlására alkalmazható amidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
RU2004132847A (ru) Способ лечения гиперсекреции слизи
JP2020527575A5 (ru)
JP2005538066A5 (ru)
WO2009059030A1 (en) Pyrazole derivatives as kinase inhibitors
EP1545514A1 (en) Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
DE60310730T2 (de) Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
US20030220336A1 (en) Method of treating mucus hypersecretion
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑